Milestone Pharmaceuticals Q3 2025 results update

Milestone Pharmaceuticals Inc. filed a report stating that on November 12, 2025 it issued a press release covering its financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

Milestone Pharmaceuticals Inc. filed a report stating that on November 12, 2025 it issued a press release covering its financial results for the third quarter ended September 30, 2025.

The press release also includes a regulatory and corporate update, giving readers insight into recent business and regulatory developments alongside the quarterly numbers. This press release is furnished as Exhibit 99.1 to the report and incorporated by reference, meaning the detailed figures and commentary are contained in that attached document.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Milestone Pharmaceuticals (MIST) disclose in this 8-K?

Milestone Pharmaceuticals Inc. disclosed that it issued a press release announcing its financial results for the third quarter ended September 30, 2025, along with a regulatory and corporate update.

Which period do the Milestone Pharmaceuticals (MIST) results cover?

The financial results discussed in the press release cover the third quarter ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for Milestone Pharmaceuticals (MIST)?

The detailed Q3 2025 financial results and related regulatory and corporate update are contained in the press release furnished as Exhibit 99.1 to this report.

What exhibit number contains the Milestone Pharmaceuticals (MIST) press release?

The press release announcing the third quarter 2025 results and updates is attached as Exhibit 99.1.

Who signed this Milestone Pharmaceuticals (MIST) report?

The report was signed on behalf of Milestone Pharmaceuticals Inc. by Amit Hasija, Chief Financial Officer.

Does this Milestone Pharmaceuticals (MIST) filing include an interactive data file?

Yes. The report lists Exhibit 104 as the Cover Page Interactive Data File, which includes the cover page XBRL tags embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 07:16 AM EST Learn about SEC filing dates

false 0001408443 A8 00-0000000 QC 0001408443 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 12, 2025

MILESTONE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Québec		001-38899		Not applicable
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1111 Dr. Frederik-Philips Boulevard,
Suite 420
Montréal, Québec CA		H4M 2X6
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (514) 336-0444

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		MIST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2025, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025, which also provided a regulatory and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 12, 2025
104		Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MILESTONE PHARMACEUTICALS INC.
	By:	/s/Amit Hasija
		Amit Hasija
		Chief Financial Officer
	Dated: November 12, 2025